Print

Lay Description

The purpose of this study is to determine the safety and efficacy of nab-paclitaxel and gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic cancer.

Category

  • Diabetes
  • Minority Studies
IRB Number
20150799HU
NCT Number
ct.gov registration not required
Open to Enrollment
Yes

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

Exclusion Criteria

Study Design

Arm Groups

Study Contact


Regulatory Point of Contact
Roy Resendez
(210) 585-9776
roy.resendez@utrgv.edu

Principal Investigator
Ravindranath Duggirala